| Bioactivity | ND-2110 is a selective IRAK4 inhibitor (Ki: 7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets the subset of activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL) cell lines with MYD88 L265P mutations,. ND-2110 inhibits LPS-induced TNF production, alleviates collagen-induced arthritis, and blocks gout formation in mouse models[1]. |
| CAS | 1388894-17-4 |
| Formula | C21H28N4O3S |
| Molar Mass | 416.54 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kelly PN, et al. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. J Exp Med. 2015 Dec 14;212(13):2189-201. |
ND-2110
CAS: 1388894-17-4 F: C21H28N4O3S W: 416.54
ND-2110 is a selective IRAK4 inhibitor (Ki:7.5 nM). ND-2110 binds to the ATP pocket of IRAK4. ND-2110 targets the subset
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.